Natera Inc. (NASDAQ:NTRA) said a federal court in Delaware has ruled that the company is entitled to a 30% ongoing royalty on certain revenues tied to infringing minimal residual disease-related product sales in its patent case against ArcherDx and Invitae.
The ruling, issued on April 6, 2026, follows an earlier injunction granted on November 21, 2023. The royalty will apply to revenue generated after the injunction from products that fall under specific exceptions to that order. Previously, a jury had set an effective royalty rate of 20.5% on revenue earned before the injunction, which remains unchanged.
The court also reaffirmed the validity of the three minimal residual disease patents at the center of the case and upheld damages associated with Invitae’s products in this segment. In addition, the jury’s findings on patent validity and direct infringement related to non-minimal residual disease products were left in place.
Natera is a precision medicine company specializing in cell-free DNA testing across oncology, women’s health and organ health. The firm holds more than 650 issued or pending patents, including several covering minimal residual disease diagnostics.